RETA–GLP3

Retatrutide is a synthetic peptide engineered as a triple receptor agonist, designed to simultaneously activate three distinct receptor pathways — the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the Glucagon receptor (GCGR). Each of these receptors plays a well-documented role in metabolic regulation, energy homeostasis, and glucose dynamics. By engaging all three pathways within a single compound, Retatrutide has become a uniquely valuable research tool for studying the combined and potentially synergistic effects of incretin and glucagon receptor co-activation on metabolic outcomes in laboratory settings.

Semaglutide is a single receptor agonist — it acts exclusively on the GLP-1 receptor. Tirzepatide, a dual agonist, adds GIP receptor activation. Retatrutide goes a step further by adding glucagon receptor agonism to the combination, making it a triple agonist. The glucagon receptor component is particularly significant from a research standpoint — glucagon receptor activation has been studied for its role in promoting hepatic fat oxidation and increasing energy expenditure, effects that are distinct from and complementary to GLP-1 and GIP receptor mediated mechanisms. This three-pathway engagement is what makes Retatrutide a mechanistically unique compound in the current research landscape.

Preclinical studies in rodent and non-human primate models have examined Retatrutide’s effects across a wide range of metabolic markers. Animal model research has documented significant reductions in body weight and visceral adipose tissue, improvements in fasting glucose and insulin sensitivity, reductions in hepatic fat content, and favorable changes in lipid profiles including triglycerides and LDL cholesterol. Researchers have noted that the magnitude of effects observed in animal models exceeded those documented with single and dual receptor agonists, which has driven substantial interest in its triple agonist mechanism as a research model for studying compounded receptor pathway engagement.

The GLP-1 receptor (GLP-1R) is expressed in the pancreas, brain, heart, and gastrointestinal tract. GLP-1R activation has been extensively studied for its role in glucose-dependent insulin secretion, glucagon suppression, gastric emptying modulation, and central nervous system satiety signaling. The GIP receptor (GIPR) is expressed in pancreatic beta cells, adipose tissue, bone, and the brain. GIPR activation research has focused on its role in potentiating insulin secretion and its effects on adipose tissue lipid storage and metabolism. The Glucagon receptor (GCGR) is expressed primarily in the liver and plays a central role in hepatic glucose production, fat oxidation, and energy expenditure. Glucagon receptor agonism in research models has been associated with increased thermogenesis and lipolysis — effects that complement and extend the metabolic impact of GLP-1 and GIP receptor co-activation.

Glucagon has historically been studied primarily in the context of its role in raising blood glucose — the opposite of insulin. However, emerging research has reframed glucagon receptor activation in a more nuanced light. In the context of triple agonism, GCGR activation has been studied for its ability to increase hepatic fat oxidation, promote thermogenesis, and drive energy expenditure independent of food intake reduction. This energy expenditure component is mechanistically distinct from GLP-1 and GIP mediated effects and represents one of the key reasons Retatrutide has attracted significant research interest as a model for studying compounded metabolic receptor engagement.

Emerging research has begun examining Retatrutide’s effects on cardiovascular markers in both animal and early human research models. Studies have investigated its effects on blood pressure, heart rate, arterial inflammation markers, and lipid profiles. GLP-1 receptor agonists as a class have an established body of cardiovascular research literature, and Retatrutide’s triple agonist profile has prompted researchers to investigate whether its additional receptor engagement produces compounding or attenuating effects on cardiovascular parameters compared to single and dual agonists.

Retatrutide is soluble in bacteriostatic water, which is the most commonly cited solvent in published research protocols for GLP-1 class peptides. Researchers should consult compound-specific solubility data and published literature to confirm the appropriate solvent and preparation methodology for their specific research application.

Every batch is independently tested for purity and identity prior to shipping. Full COA data including purity percentage and testing methodology is available via our batch lookup tool using your batch number.

Retatrutide arrives as a white to off-white lyophilized powder in a sterile sealed vial. Pharmaceutical-grade mannitol is included as a lyoprotectant, giving the powder visible bulk at the bottom of the vial. This is expected and normal.

Lyophilized (unprepared) vials: In a cool, dry environment away from direct light and heat, lyophilized vials maintain compound integrity for approximately six months to one year. For extended preservation, deep freezer storage under stable conditions without repeated temperature cycling is appropriate. Published stability data for lyophilized peptides of this class suggests integrity can be maintained for several years under optimal frozen storage conditions — researchers should consult current literature for compound-specific stability data. Avoid repeated temperature cycling as it accelerates degradation regardless of storage temperature.

Once prepared for laboratory use, refrigerated storage is standard protocol. Research and stability studies indicate that prepared peptide solutions of this class typically maintain peak integrity for approximately 28 to 40 days under refrigerated conditions. Beyond this window researchers should account for potential degradation when designing experimental protocols.

For laboratory research purposes only. Not for human consumption. Research use only.